BIIB

SEC source: 0001127602-24-019236 · form4.xml · nonDerivative · entry 1

Patolawala Monish D · CIK 0001815253 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,340

SEC source: 0001127602-24-019234 · form4.xml · nonDerivative · entry 1

Freire Maria C · CIK 0001547999 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,445

SEC source: 0001127602-24-019235 · form4.xml · nonDerivative · entry 1

HAWKINS WILLIAM A · CIK 0001106508 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,490

SEC source: 0001127602-24-019231 · form4.xml · nonDerivative · entry 1

DORSA CAROLINE · CIK 0001181174 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,607

SEC source: 0001127602-24-014199 · form4.xml · derivative · entry 3

Keeney Adam · CIK 0001973607 · Head of Corporate Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,877

Underlying: Common Stock · 938 shares

Expires 2026-05-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of May 1, 2023.

SEC source: 0001127602-24-014199 · form4.xml · nonDerivative · entry 2

Keeney Adam · CIK 0001973607 · Head of Corporate Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 662

SEC source: 0001127602-24-014199 · form4.xml · nonDerivative · entry 1

Keeney Adam · CIK 0001973607 · Head of Corporate Development

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 938

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-012414 · form4.xml · nonDerivative · entry 1

Singhal Priya · CIK 0001769608 · Head of Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,886.4761

F1 · balance_after: 1. Includes 93.3846 shares acquired under the Biogen Inc. employee stock purchase plan on 3/28/2024.

SEC source: 0001127602-24-012405 · form4.xml · derivative · entry 3

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 240 shares

Expires 2024-04-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This award was granted to the reporting person on April 1, 2021. The final portion of the awards vested on the third anniversary of the grant date.

SEC source: 0001127602-24-012405 · form4.xml · nonDerivative · entry 2

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,634.3741

SEC source: 0001127602-24-012405 · form4.xml · nonDerivative · entry 1

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,751.3741

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: 1. Includes 93.3846 shares acquired under the Biogen Inc. employee stock purchase plan on 3/28/2024.

SEC source: 0001127602-24-006947 · form4.xml · nonDerivative · entry 1

Singhal Priya · CIK 0001769608 · Head of Development

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,886.0915

SEC source: 0001127602-24-006220 · form4.xml · derivative · entry 7

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,012 shares

Expires 2024-02-18

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-24-006220 · form4.xml · derivative · entry 6

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,012

Underlying: Common Stock · 1,614 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-24-006220 · form4.xml · derivative · entry 5

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,423 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006220 · form4.xml · nonDerivative · entry 4

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,683

SEC source: 0001127602-24-006220 · form4.xml · nonDerivative · entry 3

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,464

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006220 · form4.xml · nonDerivative · entry 2

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,850

SEC source: 0001127602-24-006220 · form4.xml · nonDerivative · entry 1

ALEXANDER SUSAN H · CIK 0001263839 · EVP Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,506

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006217 · form4.xml · derivative · entry 7

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,879 shares

Expires 2024-02-18

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-24-006217 · form4.xml · derivative · entry 6

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,879

Underlying: Common Stock · 1,507 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-24-006217 · form4.xml · derivative · entry 5

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,197 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006217 · form4.xml · nonDerivative · entry 4

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,583.716

SEC source: 0001127602-24-006217 · form4.xml · nonDerivative · entry 3

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,312.716

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006217 · form4.xml · nonDerivative · entry 2

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,805.716

SEC source: 0001127602-24-006217 · form4.xml · nonDerivative · entry 1

Gregory Ginger · CIK 0001545716 · EVP, Human Resources

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,340.716

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006216 · form4.xml · derivative · entry 7

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 807 shares

Expires 2024-02-18

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-24-006216 · form4.xml · derivative · entry 6

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 807

Underlying: Common Stock · 647 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-24-006216 · form4.xml · derivative · entry 5

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,370 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006216 · form4.xml · nonDerivative · entry 4

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,701

SEC source: 0001127602-24-006216 · form4.xml · nonDerivative · entry 3

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,014

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006216 · form4.xml · nonDerivative · entry 2

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,367

SEC source: 0001127602-24-006216 · form4.xml · nonDerivative · entry 1

Izzar Rachid · CIK 0001875506 · Head of Global Product Strat.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,006

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006215 · form4.xml · derivative · entry 7

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 537 shares

Expires 2024-02-18

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-24-006215 · form4.xml · derivative · entry 6

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 537

Underlying: Common Stock · 431 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-24-006215 · form4.xml · derivative · entry 5

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 914 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006215 · form4.xml · nonDerivative · entry 4

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,226.7483

SEC source: 0001127602-24-006215 · form4.xml · nonDerivative · entry 3

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,353.7483

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006215 · form4.xml · nonDerivative · entry 2

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,922.7483

SEC source: 0001127602-24-006215 · form4.xml · nonDerivative · entry 1

Kramer Robin · CIK 0001609222 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,191.7483

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006214 · form4.xml · derivative · entry 7

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,684 shares

Expires 2024-02-18

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-24-006214 · form4.xml · derivative · entry 6

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,684

Underlying: Common Stock · 2,152 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represented the maximum possible number of shares that were eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-24-006214 · form4.xml · derivative · entry 5

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,568 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006214 · form4.xml · nonDerivative · entry 4

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,406

SEC source: 0001127602-24-006214 · form4.xml · nonDerivative · entry 3

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,507

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006214 · form4.xml · nonDerivative · entry 2

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,355

SEC source: 0001127602-24-006214 · form4.xml · nonDerivative · entry 1

MCDONNELL MICHAEL R · CIK 0001121897 · EVP, Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,692

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-24-006213 · form4.xml · derivative · entry 7

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 504 shares

Expires 2024-02-18

F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-24-006213 · form4.xml · derivative · entry 6

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 504

Underlying: Common Stock · 404 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This award was granted to the reporting person on February 18, 2021. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

SEC source: 0001127602-24-006213 · form4.xml · derivative · entry 5

Murphy Nicole · CIK 0001910644 · Head of Pharm Ops and Tech

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 856 shares

Expires 2024-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.